Pittsburgh Business Group on Health’s LivingMyLife program to expand
PITTSBURGH The Pittsburgh Business Group on Health’s LivingMyLife program, which helps diabetes patients with disease management through the use of “coach pharmacists,” will soon do the same for those with other diseases, according to published reports.
The Pittsburgh Tribune-Review reported Friday that LivingMyLife also would help patients with asthma and heart disease. The program, which began in 2006, allows patients to manage their disease with visits to pharmacies, mostly Giant Eagle, Kmart and some independents.
The announcement was made at the annual healthcare symposium of the group and involved more than 100 attendees, the newspaper reported.
Safeway raises $11.2 million for muscular dystrophy
PLEASANTON, Calif. Safeway announced Wednesday that it raised $11.2 million to benefit the Muscular Dystrophy Association during MDA’s annual Labor Day Telethon.
Safeway dedicates each April and August to bringing awareness to helping people with disabilities. Easter Seals and Special Olympics are among the organizations who receive the donations raised in April, with the August campaign dedicated to the work of MDA. Over the years, Safeway has raised more than $58 million for muscular dystrophy charities through customer donations at checkout and grassroots efforts, including walks and golf tournaments.
“Thanks to the generosity of our customers and the enthusiasm of our employees, we are making an important difference in the lives of individuals and families coping with debilitating neuromuscular diseases,” said Safeway EVP Larree Renda, who also is an MDA national VP. “MDA’s outreach is without limit, and the results of MDA-funded research are nothing short of amazing. I am confident we will see a cure for neuromuscular disease in our lifetime, and MDA will be at the center of that cure.”
Hi-Tech Pharmacal posts $3 million loss
AMITYVILLE, N.Y. Hi-Tech Pharmacal had $40.4 million in sales during its fiscal first quarter ended July 31, the generic drug maker said Thursday. The numbers amounted to a decrease of $3 million from the same period in 2009.
The bulk of the company’s sales came from generic drugs, which had sales of $32.3 million, a $4.4 million decrease from the year before. The decrease mostly resulted from declines in sales of the eye treatments dorzolamide and timolol ophthalmic solution, or dorzolamide ophthalmic solution, whose sales declined by $7.9 million because of a significant reduction in price. At the same time, sales increases of fluticasone propionate nasal spray helped offset the decline.
Sales for the ECR Pharmaceuticals division were $3.5 million, a $241,000 increase over the year before, resulting from higher sales of the Lodrane (brompheniramine) line of allergy drugs, despite a decrease in sales of the DexPak (dexamethasone) line of corticosteroids.
Midlothian Labs, which markets niche generic drugs, had sales of around $1 million, a $340,000 decrease from the year before, while sales for the Health Care Products division, which markets over-the-counter products, were $3.5 million, a $1.4 million increase from the year before.